New Frontiers in the Management of Acute Myeloid
Leukemia (AML): Exploring Emerging Treatment Options

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Jazz Pharmaceuticals, Inc and Novartis Pharmaceuticals

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, its incidence is expected to increase as the population ages. Fortunately the treatment paradigm in AML is set to drastically change as many new treatments are on the horizon, including the first novel therapy that has been approved since 1990. This is especially important as AML has several mutation subtypes that influence treatment selection and prognosis. Emerging treatments focus on certain mutations, including FLT3, and have shown improved efficacy and safety outcomes in clinical trial research.

Upon Completion of this activity, participants will be able to:

  • Examine key clinical trial information, including mechanisms of action, safety, and efficacy data, on emerging cytotoxic and targeted agents in the treatment of acute myeloid leukemia (AML)

  • Explore the unmet need related to existing treatment paradigms for patients with AML

  • Identify agents undergoing regulatory review or late‐phase clinical trials being studied as possible treatments for AML

  • Compare and contrast emerging treatment approaches for patients with AML younger than 60 years and patients older than 60 years

  • Evaluate available clinical data on novel agents and combination regimens being investigated in high-risk AML

Faculty: Tapan M. Kadia, MD
Assistant Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center


Dr. Kadia serves on an advisory board for Jazz Pharmacueticals and acts as a consultant with Novartis Pharmacuticals and Pfizer. He also recieves grants for research support from Bristol-Meyers Squibb, Celgene, Pfizer, and Sanofi. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Jazz Pharmaceuticals, Inc and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue